With improvement in treatment options and supportive care, patients with MM are living longer. The majority of patients with MM are at risk for both osteolytic bone lesions and osteoporosis.

The heterogeneity of relapsed/refractory multiple myeloma (MM) and an increasing number of therapeutic options in this setting has resulted in a complex environment for treatment decisions. Multiple factors need to be considered when determining the next best therapy.

The introduction of new treatment options in multiple myeloma (MM) has led to marked improvements in overall outcomes of patients.

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma.

The development of new and innovative cancer treatments has expanded the options available to manage patients with cancer.  However, with these advances come challenges for healthcare providers and patients.

Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.